One-Year Echocardiographic Follow-Up in Transthyretin Cardiac Amyloidosis: Impact of Tafamidis Treatment

Restelli, D.; Van Wallendael, C.; De Marneffe, N.; Damas, F.; Dulgheru, R.; Lancellotti, P. One-Year Echocardiographic Follow-Up in Transthyretin Cardiac Amyloidosis: Impact of Tafamidis cardiac amyloidosis; Tafamidis; echocardiography

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Restelli, Davide; Department of Cardiology, Valvular Diseases and Cardiomyopathy Clinic, University of Liège Hospital-CHU Sart Tilman, Liège, Belgium

VAN WALLENDAEL, Céline ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie

de Marneffe, Nils ; Université de Liège - ULiège > Département des sciences cliniques

DAMAS, François ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie

Dulgheru, Raluca Elena ; Université de Liège - ULiège > Département des sciences cliniques

Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation

Language :

English

Title :

One-Year Echocardiographic Follow-Up in Transthyretin Cardiac Amyloidosis: Impact of Tafamidis Treatment

Publication date :

25 February 2025

Journal title :

Journal of Clinical Medicine

eISSN :

2077-0383

Publisher :

MDPI

Volume :

Issue :

Pages :

1538

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://www.mdpi.com/2077-0383/14/5/1538/pdf

Commentary :

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license

Available on ORBi :

since 07 April 2025

Statistics

Number of views

64 (3 by ULiège)

Number of downloads

25 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Aimo A. Merlo M. Porcari A. Georgiopoulos G. Pagura L. Vergaro G. Sinagra G. Emdin M. Rapezzi C. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies Eur. J. Heart Fail. 2022 24 2342 2351 10.1002/ejhf.2532
Garcia-Pavia P. Sultan M.B. Gundapaneni B. Sekijima Y. Perfetto F. Hanna M. Witteles R. Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study JACC Heart Fail. 2024 12 150 160 10.1016/j.jchf.2023.08.032 37943223
de Marneffe N. Dulgheru R. Ancion A. Moonen M. Lancellotti P. Cardiac amyloidosis: A review of the literature Acta Cardiol. 2022 77 683 692 10.1080/00015385.2021.1992990 35852493
Garcia-Pavia P. Rapezzi C. Adler Y. Arad M. Basso C. Brucato A. Burazor I. Caforio A.L. Damy T. Eriksson U. et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases Eur. Heart J. 2021 42 1554 1568 10.1093/eurheartj/ehab072 33825853
Martinez-Naharro A. Hawkins P.N. Fontana M. Cardiac amyloidosis Clin. Med. 2018 18 (Suppl. 2) s30 s35 10.7861/clinmedicine.18-2-s30
Carroll A. Dyck P.J. de Carvalho M. Kennerson M. Reilly M.M. Kiernan M.C. Vucic S. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis J. Neurol. Neurosurg. Psychiatry 2022 93 668 678 10.1136/jnnp-2021-327909
Maurer M.S. Schwartz J.H. Gundapaneni B. Elliott P.M. Merlini G. Waddington-Cruz M. Kristen A.V. Grogan M. Witteles R. Damy T. et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy N. Engl. J. Med. 2018 379 1007 1016 10.1056/NEJMoa1805689 30145929
Elliott P. Drachman B.M. Gottlieb S.S. Hoffman J.E. Hummel S.L. Lenihan D.J. Ebede B. Gundapaneni B. Li B. Sultan M.B. et al. Long-Term Survival with Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy Circ. Heart Fail. 2022 15 e008193 10.1161/CIRCHEARTFAILURE.120.008193 34923848
Garcia-Pavia P. Bengel F. Brito D. Damy T. Duca F. Dorbala S. Nativi-Nicolau J. Obici L. Rapezzi C. Sekijima Y. et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy Eur. J. Heart Fail. 2021 23 895 905 10.1002/ejhf.2198
Ichikawa Y. Oota E. Odajima S. Kintsu M. Todo S. Takeuchi K. Yamauchi Y. Shiraki H. Yamashita K. Fukuda T. et al. Impact of Tafamidis on Echocardiographic Cardiac Function of Patients With Transthyretin Cardiac Amyloidosis Circ. J. 2023 87 508 516 10.1253/circj.CJ-22-0683 36878601
Giblin G.T. Cuddy S.A.M. González-López E. Sewell A. Murphy A. Dorbala S. Falk R.H. Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis Eur. Heart J. Cardiovasc. Imaging 2022 23 1029 1039 10.1093/ehjci/jeac049
Nishizawa R.H. Kawano H. Yoshimuta T. Eguchi C. Kojima S. Minami T. Sato D. Eguchi M. Okano S. Ikeda S. et al. Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis Eur. Heart J. Cardiovasc. Imaging 2024 25 678 686 10.1093/ehjci/jead344 38109497
Tomasoni D. Bonfioli G.B. Aimo A. Adamo M. Canepa M. Inciardi R.M. Lombardi C.M. Nardi M. Pagnesi M. Riccardi M. et al. Treating amyloid transthyretin cardiomyopathy: Lessons learned from clinical trials Front. Cardiovasc. Med. 2023 10 1154594 10.3389/fcvm.2023.1154594 37288260
Adams D. Gonzalez-Duarte A. O’Riordan W.D. Yang C.C. Ueda M. Kristen A.V. Tournev I. Schmidt H.H. Coelho T. Berk J.L. et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis N. Engl. J. Med. 2018 379 11 21 10.1056/NEJMoa1716153
Lohrmann G. Pipilas A. Mussinelli R. Gopal D.M. Berk J.L. Connors L.H. Vellanki N. Hellawell J. Siddiqi O.K. Fox J. et al. Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis J. Card. Fail. 2020 26 753 759 10.1016/j.cardfail.2019.11.024 31805416
Shah S.J. Fine N. Garcia-Pavia P. Klein A.L. Fernandes F. Weissman N.J. Maurer M.S. Boman K. Gundapaneni B. Sultan M.B. et al. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy JAMA Cardiol. 2024 9 25 10.1001/jamacardio.2023.4147 37966817
Wu F. Zhu H. Zhang Y. Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system Sci. Rep. 2024 14 13691 10.1038/s41598-024-64697-y 38871835